THAR Form 3: Director Thomas Kahler Reports 50,000 Stock Options
Rhea-AI Filing Summary
Tharimmune director Thomas Clay Kahler filed an initial Form 3 reporting ownership of a derivative security: a stock option to buy 50,000 shares of Tharimmune common stock (ticker THAR) with an exercise price of $1.33. The option has an expiration date of 08/04/2035; 25,000 shares vested on grant and 25,000 vest on 08/04/2026. The Form 3 indicates the filing was made by one reporting person.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider initial ownership disclosure of options by a company director; standard vesting schedule disclosed.
This Form 3 is a standard initial Section 16 filing showing a director-level option grant rather than open-market purchases or transfers. The grant size (50,000 options) and exercise price ($1.33) are stated, with half vesting immediately and half vesting one year later. For governance review, this confirms timely disclosure of equity compensation but contains no additional material events such as related-party transactions or unusual acceleration terms.
TL;DR: Compliance disclosure appears complete for an initial beneficial-ownership report; no discrepancies visible in the filing text.
The filing identifies the reporting person, address, relationship to issuer (Director), event date (04/28/2025), and option mechanics (exercise price, underlying shares, expiration). The signature block is present with a signature date of 08/22/2025. From a compliance standpoint, this is a routine public record of equity compensation under Section 16 requirements and does not by itself implicate trading violations.